The Turkish Competition Board (“Board”) decided that Novartis and Roche violated Article 4 of the Law No. 4054 on the Protection of Competition (“Law No. 4054”) by way of engaging in concerted practice to expand the use of Lucentis as opposed to Altuzan, both of which are the drugs used for the treatment of eye diseases, while Lucentis is more expensive than Altuzan [1]. In its competitive assessment, the Board firstly examined whether Altuzan and Lucentis can be considered as competing products. Having found that Altuzan and Lucentis are competing products, the Board assessed that the conducts of Novartis and Roche amount to a concerted practice and imposed administrative fines on the said undertakings. Background The preliminary investigation against Novartis and Roche was initiated
Partager sur
|
|
The Turkish Competition Authority imposes fines on two pharmaceutical companies for engaging in concerted practices to expand the use of Lucentis as opposed to Altuzan in treating eye diseases (Roche / Novartis)
L'accès à cet article est réservé aux abonnés
Déjà abonné ? Identifiez-vous
L’accès à cet article est réservé aux abonnés.
Lire gratuitement un article
Vous pouvez lire cet article gratuitement en vous inscrivant.
